Glioma Diagnosis Goes Molecular, But Most of the World Cannot Afford It

A diagnosis of glioma has never been simple. These tumors, the most common and aggressive primary cancers of the central nervous system, have for decades been classified by what pathologists could see under a microscope. That era is over. The fifth edition of the WHO Classification of Tumors of the Central Nervous System, published in 2021 and updated in 2022 for adult-type diffuse gliomas, formally redefined glioma taxonomy around molecular signatures rather than histological appearance alone. A critical review published in Annals of Clinical and Translational Neurology now argues that this diagnostic revolution, while scientifically transformative, has exposed a stark global inequity: the molecular tests that define modern glioma care remain inaccessible to the vast majority of patients worldwide, and the price of that gap is measured in wasted therapies, lost survival, and a distorted picture of the disease itself.

The molecular logic of the new classification rests on a small set of defining alterations. Adult-type diffuse gliomas are now divided into three primary entities. Astrocytoma, IDH-mutant is characterized by mutations in the IDH1 or IDH2 genes, typically accompanied by ATRX and TP53 alterations and the absence of 1p/19q codeletion; its grading incorporates the presence of CDKN2A/B homozygous deletion, which confers a grade 4 designation regardless of histology. Oligodendroglioma requires the dual signature of IDH mutation and whole-arm 1p/19q codeletion. Glioblastoma, IDH-wildtype, the most aggressive form, can be diagnosed in any IDH-wildtype diffuse glioma carrying a TERT promoter mutation, EGFR amplification, or the characteristic +7/−10 cytogenetic pattern, even without classic histological features. Pediatric-type gliomas, driven by histone H3 alterations or MAPK pathway dysregulation, form their own molecularly coherent categories. Each of these definitions depends on tests that go far beyond conventional histopathology.

The major international guidelines have converged on this framework. The WHO CNS5, the National Comprehensive Cancer Network, the European Association of Neuro-Oncology, and the Italian Association of Neuro-Oncology all designate IDH1/2 mutation testing as essential, with 1p/19q codeletion assessment required whenever an IDH-mutant tumor is identified. TERT promoter mutation, EGFR amplification, and +7/−10 status are required to establish a glioblastoma diagnosis under WHO criteria, while MGMT promoter methylation is recommended as a predictive biomarker for temozolomide response. The Italian guidelines go further operationally, defining mandatory core tests, integrated grading that incorporates CDKN2A/B deletion, and structured flowcharts that standardize reporting from tissue handling through molecular testing to final integrated diagnosis. On paper, the global standard is clear and consistent.

The problem is that the technologies needed to meet that standard are unevenly distributed. Immunohistochemistry, the workhorse of pathology, costs roughly €290 per test and can detect IDH1 R132H, ATRX loss, p53 accumulation, and H3 K27M within one to two days in a standard pathology laboratory. Fluorescence in situ hybridization, at approximately €795, visualizes 1p/19q deletion and EGFR amplification with high specificity. PCR-based methods, including quantitative PCR, multiplex ligation-dependent probe amplification, and digital PCR, cost between roughly €261 and €600 and cover an impressive range of essential biomarkers, from whole-arm 1p/19q codeletion to TERT promoter mutations and MGMT methylation. Targeted next-generation sequencing panels, at around €1538, offer broader characterization but demand sequencing platforms, bioinformatics infrastructure, and specialized staff. Genome-wide DNA methylation profiling, costing €2000 to €3000 per test, remains concentrated in a handful of reference centers.

Surveys from the Asian Oceanian Society of Neuropathology paint a sobering picture of who can actually access these tools. Fewer than 15 percent of centers in low- and middle-income countries have access to next-generation sequencing, and methylation profiling is virtually absent. Most institutions in these settings rely on immunohistochemistry and limited PCR-based assays. Even within high-income nations, access is stratified: rural and community hospitals in Europe often lack next-generation sequencing and methylation platforms, while in the United States substantial disparities persist between academic institutions and community hospitals in bioinformatics capacity, reimbursement, and neuropathology expertise. In China, genomic capacity has expanded rapidly in major urban centers, yet the ratio of sequencing-capable facilities to population varies by an order of magnitude between coastal metropolitan areas and inland provinces. Japan and South Korea have achieved broader access through national insurance reimbursement for targeted panels, though regional concentration remains pronounced.

The review is emphatic that this is not simply a story of rich centers versus poor ones. The authors argue that presenting sequencing and methylation arrays as universal gold standards reflects the practice of a minority of well-resourced institutions and does not align with global diagnostic realities. For the majority of glioma patients, a tiered strategy built on immunohistochemistry, PCR-based assays, and multiplex ligation-dependent probe amplification yields all the clinically actionable information needed for diagnosis, grading, and treatment planning. Each technique occupies a distinct niche: multiplex ligation-dependent probe amplification remains particularly useful for whole-arm 1p/19q assessment, while digital PCR offers exceptional sensitivity for low-allele-fraction variants such as TERT promoter mutations. No single modality addresses every diagnostic question, and the appropriate test should be determined by the clinical question, not by the available technology.

The economics of inaction are striking. A single cycle of temozolomide administered to a patient whose glioblastoma lacks MGMT promoter methylation, and who therefore derives minimal benefit, often costs more than the methylation assay itself. Without testing, temozolomide is given empirically to all glioblastoma patients despite limited benefit in roughly 60 percent of unmethylated cases. Patients with 1p/19q-codeleted oligodendroglioma who do not receive procarbazine, lomustine, and vincristine chemotherapy with radiation may lose years of survival compared with those treated according to molecular subtype. Misclassification cascades into ineffective therapies, unnecessary toxicity, accelerated progression, earlier salvage treatment, more emergency admissions, and ultimately greater disability, caregiver burden, and lost productivity. The cumulative societal cost of diagnostic inaccuracy, the review concludes, dwarfs the upfront investment in molecular testing.

The consequences extend beyond individual treatment decisions into the research enterprise itself. Contemporary glioma trials are increasingly molecularly driven, and centers without testing capability cannot screen or enroll eligible patients, producing what the authors call diagnostic deserts and trial deserts, regions where patients are excluded from cutting-edge research not because of clinical ineligibility but because of missing infrastructure. Historical trials conducted without molecular stratification are now difficult to interpret, since treatment benefits are often confined to molecular subgroups. Biobanks lacking molecular annotation have limited value for biomarker discovery. At a global scale, the published molecular landscape of gliomas is heavily biased toward populations served by well-resourced centers, potentially overlooking biological features unique to underrepresented regions.

The barriers to change form a self-reinforcing cycle. High costs and unstable funding restrict the test menu and force dependence on send-out testing with long turnaround times. Shortages of neuropathologists, molecular biologists, and bioinformaticians, worsened by brain drain to high-income countries, lead to errors in test selection and interpretation. Non-standardized tissue fixation and inadequate quality control compromise sample integrity, while bureaucratic delays in approving and reimbursing new tests slow adoption. Limited exposure to the full spectrum of diagnostic modalities then prevents local expertise from developing, perpetuating the cycle from the beginning.

The proposed remedy is a three-tiered framework rather than a demand for universal high-end sequencing. Tier 1, essential and universally accessible, combines histopathology and immunohistochemistry with qPCR, multiplex ligation-dependent probe amplification, or digital PCR for the core biomarkers, delivering actionable results in one to five days with minimal bioinformatics. Tier 2 provides targeted sequencing panels through regional hub laboratories for ambiguous cases and trial candidates. Tier 3 concentrates methylation profiling in reference centers serving large populations. Supporting strategies include hub-and-spoke networks endorsed by the Lancet Commission on Diagnostics, telepathology platforms that allow remote expert interpretation, health technology assessments that explicitly weigh the cost of non-implementation, and workforce initiatives such as the MNP Outreach program, which offers free methylation testing to more than 300 patients annually in Pakistan. The authors also call on the WHO to promote regional reference laboratories, define a minimum diagnostic standard achievable with Tier 1 technologies, and negotiate affordable reagent pricing. The central message is one of pragmatic optimism: an accurate, clinically actionable glioma diagnosis is achievable today for most patients using existing, affordable technologies, provided the political will and organizational frameworks exist to deliver them. The alternative is a consolidated two-tiered neuro-oncology in which access to precision medicine is determined by geography rather than need.

Subject of Research: Global disparities in the implementation of molecular diagnostics for glioma classification under the WHO CNS5 framework

Article Title: The Price of Precision: A Critical Review of Molecular Diagnostics in Glioma, From Guidelines to Global Disparities

Article References: Guarnaccia, M., & Cavallaro, S. (2026). The Price of Precision: A Critical Review of Molecular Diagnostics in Glioma, From Guidelines to Global Disparities. Annals of Clinical and Translational Neurology, 13(10), 1968-1977. https://doi.org/10.1002/acn3.70503

Image Credits: AI Generated

DOI: 10.1002/acn3.70503

Keywords: glioma, molecular diagnostics, WHO CNS5, IDH mutation, 1p/19q codeletion, glioblastoma, health economics, global health disparities, next-generation sequencing, MGMT methylation, neuro-oncology, LMICs